Clinical trials: Breast Cancer
Breast Cancer
Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT00616967
- Testing
- carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, vorinostat
- Where
- 5 sites in United States
- Volunteers
- 68 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Colorectal Cancer, Metastatic Breast Cancer
Evaluation of Hypertension as a Predictor of Efficacy Bevacizumab in Metastatic Breast Cancer and Colorectal Cancer
This is a multicenter, post-authorization observational with prospective follow-up (EPA-SP) study. Will be involved 137 metastatic breast cancer patients or metastatic colorectal cancer.
- Trial name
- BRECOL (NCT01733628)
- Where
- 10 sites in Spain
- Volunteers
- 143 people
- Sponsor
- Spanish Breast Cancer Research Group
Breast Cancer
Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer
HER2 is a protein that sits on the surface of breast cancer cells in some people. Because you are one of these people, your breast cancer is called "HER2-positive." The HER2 protein is involved in the growth of your breast…
- Trial name
- NCT00721630
- Testing
- capecitabine, lapatinib
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer
This is a randomized, placebo-controlled, double-blind, phase II trial of nab-paclitaxel with or without mifepristone for advanced, glucocorticoid receptor-positive, triple-negative breast cancer.
- Trial name
- NCT02788981
- Testing
- Mifepristone, Nab-Paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- University of Chicago
Breast Cancer
Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
This trial will examine the combination of sunitinib plus paclitaxel and carboplatin as neoadjuvant treatment for locally advanced breast cancer.
- Trial name
- NCT00887575
- Testing
- Paclitaxel, Carboplatin, Sunitinib
- Where
- 14 sites in United States
- Volunteers
- 54 people
- Sponsor
- SCRI Development Innovations, LLC
Locally Advanced Breast Cancer, Metastatic Breast Cancer
Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab
The goal of this national, multicenter single arm phase II clinical trial is to study the efficacy, safety and tolerability of the administration of Trastuzumab Deruxtecan (T-DXd) in HER2-positive locally advanced or metastatic…
- Trial name
- TRANSCENDER (NCT05744375)
- Testing
- Trastuzumab deruxtecan
- Where
- 19 sites in Spain
- Volunteers
- 2 people
- Sponsor
- Spanish Breast Cancer Research Group
Breast Cancer
A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer
This 2 arm study compared the efficacy and safety of label dose of capecitabine (Xeloda®) to that of a lower dose of Xeloda® plus docetaxel (Taxotere®) in patients with locally advanced or metastatic breast cancer after failure…
- Trial name
- NCT00077857
- Testing
- capecitabine (Xeloda®), docetaxel (Taxotere®)
- Where
- 94 sites in United States, Bosnia and Herzegovina and 7 more
- Volunteers
- 470 people
- Sponsor
- Hoffmann-La Roche
Early Breast Cancer
A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)
The current study will compare PK, efficacy, safety, and immunogenicity of PF-05280014 (Trastuzumab-Pfizer) in combination with Taxotere® and Carboplatin (Paraplatin) versus Herceptin® (Trastuzumab-EU) approved in the EU in…
- Trial name
- NCT02187744
- Testing
- PF-05280014, Taxotere®, Paraplatin®
- Where
- 52 sites in United States, Belarus and 8 more
- Volunteers
- 226 people
- Sponsor
- Pfizer
Breast Cancer, Doxorubicin Induced Cardiomyopathy
99mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast Cancer
This was a single center, proof-of-concept (PoC), Phase II study. Patients with histologically confirmed early stage (Stage I, II or III) HER-2 negative breast cancer and scheduled to receive doxorubicin-based (neo)adjuvant…
- Trial name
- NCT02677714
- Testing
- 99mTc-rhAnnexin V-128
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- Advanced Accelerator Applications
Triple Negative Breast Neoplasms
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss
The purpose of this study was to determine whether treatment with alpelisib in combination with nab-paclitaxel is safe and effective in subjects with advanced triple negative breast cancer (aTNBC) who carry either a PIK3CA…
- Trial name
- EPIK-B3 (NCT04251533)
- Testing
- alpelisib, nab-paclitaxel
- Where
- 78 sites in United States, Argentina and 28 more
- Volunteers
- 137 people
- Sponsor
- Novartis Pharmaceuticals
HER2/Neu Negative, No Evidence of Disease
Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission
This phase I trial studies the side effects and best dose of a vaccine therapy in preventing cancer from coming back in patients with non-metastatic, node positive, human epidermal growth factor receptor (HER)2 negative breast…
- Conditions
- HER2/Neu Negative, No Evidence of Disease, One or More Positive Axillary Nodes, Stage IB Breast Cancer
- Trial name
- WOKVAC (NCT02780401)
- Testing
- Laboratory Biomarker Analysis, pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine, Sargramostim
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- University of Washington
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Phase II Study of Everolimus Beyond Progression
This phase II trial studies how well everolimus and hormone therapy work in treating patients with hormone receptor positive breast cancer that has continued to spread (progressed) or returned after a period of improvement…
- Conditions
- Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT02269670
- Testing
- everolimus, anastrozole, letrozole
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Emory University
Breast Cancer
Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)
Study of efficacy of nivolumab with neoadjuvant chemotherapy in patients with IBC
- Trial name
- NCT03742986
- Testing
- Nivolumab 360mg, Paclitaxel 80mg/m^2, Doxorubicin 60mg/m^2
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- NYU Langone Health
Non-Small Cell Lung Cancer, Triple-negative Breast Cancer
Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC
Part 1of the study will evaluate the safety, pharmacokinetics, pharmacodynamics and immunogenicity of increasing doses of a vaccine-based immunotherapy regimen (VBIR-2) for patients with advanced or metastatic non-small cell lung…
- Trial name
- NCT03674827
- Testing
- PF-06936308
- Where
- 34 sites in United States
- Volunteers
- 36 people
- Sponsor
- Pfizer
Arthralgia, Breast Cancer
S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy
RATIONALE: An omega-3 fatty acid-enriched nutritional supplement may help improve muscle and bone pain and stiffness caused by hormone therapy in patients with breast cancer.
- Conditions
- Arthralgia, Breast Cancer, Pain
- Trial name
- NCT01385137
- Testing
- omega-3 fatty acid
- Where
- 292 sites in United States
- Volunteers
- 262 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer
The PIONEER-01 Study of the Imagio Breast Imaging System
This is a prospective controlled multi-center study involving gray scale (B-mode) ultrasound vs OA/US (opto-acoustic and gray scale ultrasound) for the visualization of suspicious masses.
- Trial name
- NCT01943916
- Testing
- Imagio OA/US (US and OA/US), Imagio gray scale ultrasound
- Where
- 16 sites in United States
- Volunteers
- 2,105 people
- Sponsor
- Seno Medical Instruments Inc.
Solid Tumor, Clear Cell Renal Cell Carcinoma
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
This is a Phase 1b/2 study to determine the recommended phase 2 dose (RP2D), safety and tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor CB-839 with the poly adenosine diphosphate ribose…
- Conditions
- Solid Tumor, Clear Cell Renal Cell Carcinoma, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer
- Trial name
- NCT03875313
- Testing
- CB-839, Talazoparib
- Where
- 9 sites in United States
- Volunteers
- 33 people
- Sponsor
- Calithera Biosciences, Inc
Breast Cancer, Vaginal Dryness
Pilocarpine in Treating Vaginal Dryness in Patients With Breast Cancer
RATIONALE: Pilocarpine may decrease vaginal dryness and improve quality of life in patients with breast cancer It is not yet known whether pilocarpine is more effective than a placebo in treating vaginal dryness in patients with…
- Trial name
- NCT00343382
- Testing
- pilocarpine hydrochloride
- Where
- 192 sites in United States
- Volunteers
- 201 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- SOLE (NCT00553410)
- Testing
- Letrozole
- Where
- 164 sites in United States, Australia and 18 more
- Volunteers
- 4,884 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer
A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer
This 2 arm study will compare the efficacy and safety of Taxotere + Xeloda, versus Taxotere alone, following a regimen of Adriamycin plus Cytoxan in women with high-risk breast cancer.
- Trial name
- NCT00089479
- Testing
- capecitabine [Xeloda], Taxotere
- Where
- United States
- Volunteers
- 2,611 people
- Sponsor
- Hoffmann-La Roche